RISK OF RECURRENCE AMONG PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE, EARLY BREAST CANCER RECEIVING ADJUVANT ENDOCRINE THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS

被引：0
|
作者：
Ramirez, Oliva A. [1 ]
Law, E. H. [2 ]
Cueto, J. [2 ]
Salvo, E. M. [1 ]
Situ, A. [1 ]
Samjoo, I. A. [1 ]
机构：
[1] EVERSANA, Burlington, ON, Canada
[2] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN43
引用
收藏
页码：S429 / S429
页数：1
相关论文
共 50 条
  • [31] ASCO 2019-Personal highlights on adjuvant breast cancer: (neo-)adjuvant therapy of HER2-negative HR-positive BC
    Beslija, Semir
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2019, 12 (04) : 305 - 307
  • [32] Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer
    Pronzato, Paolo
    FUTURE ONCOLOGY, 2017, 13 (16) : 1371 - 1384
  • [33] Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
    Shohei Shikata
    Takeshi Murata
    Masayuki Yoshida
    Hiromi Hashiguchi
    Yukiko Yoshii
    Ayumi Ogawa
    Chikashi Watase
    Sho Shiino
    Hirokazu Sugino
    Kenjiro Jimbo
    Akiko Maeshima
    Eriko Iwamoto
    Shin Takayama
    Akihiko Suto
    Scientific Reports, 13
  • [34] Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
    Shikata, Shohei
    Murata, Takeshi
    Yoshida, Masayuki
    Hashiguchi, Hiromi
    Yoshii, Yukiko
    Ogawa, Ayumi
    Watase, Chikashi
    Shiino, Sho
    Sugino, Hirokazu
    Jimbo, Kenjiro
    Maeshima, Akiko
    Iwamoto, Eriko
    Takayama, Shin
    Suto, Akihiko
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [35] Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer
    Hashimoto, Kazuki
    Shimomura, Akihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (13) : 1506 - +
  • [36] First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
    Shimoi, Tatsunori
    Sagara, Yasuaki
    Hara, Fumikata
    Toyama, Tatsuya
    Iwata, Hiroji
    BREAST CANCER, 2020, 27 (03) : 340 - 346
  • [37] First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
    Tatsunori Shimoi
    Yasuaki Sagara
    Fumikata Hara
    Tatsuya Toyama
    Hiroji Iwata
    Breast Cancer, 2020, 27 : 340 - 346
  • [38] Patient-reported healthcare utilization among Medicare beneficiaries with HR-positive, HER2-negative early breast cancer
    Calip, G. S.
    Cueto, J.
    Hoskins, K. F.
    Ko, N. Y.
    Zhou, J.
    Deng, H.
    Naing, K.
    Nabulsi, N. A.
    Hubbard, C. C.
    Mitra, D.
    Law, E. H.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S108 - S109
  • [39] Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study
    Guerrero-Zotano, A.
    Perez-Garcia, J. M.
    Ruiz-Borrego, M.
    Bermejo, B.
    Gil-Gil, M.
    de la Haba, J.
    Conejo, E. Alba
    Quiroga, V
    Caranana, V
    Urruticoechea, A.
    Morales, S.
    Bellet, M.
    Anton, A.
    Fernandez-Abad, M.
    Sanchez-Rovira, P.
    Calabuig, L.
    Perez-Escuredo, J.
    Sampayo-Cordero, M.
    Cortes, J.
    Llombart-Cussac, A.
    ESMO OPEN, 2024, 9 (10)
  • [40] Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk
    Bae, Soong June
    Ahn, Sung Gwe
    Ji, Jung Hwan
    Chu, Chihhao
    Kim, Dooreh
    Lee, Janghee
    Cha, Yoon Jin
    Jeong, Joon
    CANCERS, 2021, 13 (16)
12345